Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-32,700
Closed -$1.54M 11108
2025
Q3
$1.54M Buy
+32,700
New +$1.58M ﹤0.01% 5204
2025
Q2
Sell
-30,000
Closed -$1.66M 10797
2025
Q1
$1.66M Buy
+30,000
New +$1.62M ﹤0.01% 4859
2024
Q4
Sell
-10,000
Closed -$576K 10355
2024
Q3
$576K Buy
+10,000
New +$540K ﹤0.01% 5115
2015
Q3
Sell
-400
Closed -$20K 8613
2015
Q2
$20K Sell
400
-5,300
-93% -$269K ﹤0.01% 6872
2015
Q1
$282K Sell
5,700
-2,300
-29% -$110K ﹤0.01% 4606
2014
Q4
$365K Buy
+8,000
New +$388K ﹤0.01% 4482

Other funds holding SNY

UBS Group's SNY Position: Q1 2026 in Review

UBS Group reduced its Sanofi (SNY) stake by 19% in Q1 2026, selling an estimated $11.1M and leaving 983,846 shares worth $47.4M. The position accounts for 0.01% of the portfolio, ranked #1701.

UBS Group first reported a position in SNY in Q4 2014 and has held it in 46 quarters since. The position peaked at $89M in Q1 2015. 738 funds tracked by Wall St. Rank hold SNY as of Q1 2026.

  • UBS Group held 983,846 shares of Sanofi worth $47.4M as of Q1 2026.
  • UBS Group sold 238,157 Sanofi shares in Q1 2026, an estimated $11.1M.
  • Sanofi made up 0.01% of UBS Group's portfolio in Q1 2026, its #1701 holding.
  • UBS Group first reported a position in Sanofi in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Sanofi position peaked at $89M in Q1 2015.
  • 738 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.